← feed

Is NCT03533387 results overdue?

Yes — results are overdue. Primary completion was 2018-07-06; the FDAAA-801 reporting deadline (2019-07-06) passed 2588 days ago and no results are posted on ClinicalTrials.gov.

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

NCT IDNCT03533387 ↗
SponsorMediciNova (INDUSTRY)
Public issuerMEDICINOVA INC — MNOV (CIK 0001226616) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-07-06 (ACTUAL)
Reporting deadline2019-07-06 (completion + 365d)
Days overdue2588
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-07-08 · SHA-256 b2caa5b12c7cd7eb… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03533387. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →